CR20200061A - Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) - Google Patents
Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)Info
- Publication number
- CR20200061A CR20200061A CR20200061A CR20200061A CR20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dlbcl
- patients
- new
- obinutuzumab
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a obinutuzumab (o sus equivalentes funcionales) para el uso en el tratamiento de un paciente con DLBCL definido por biomarcador particular y un subgrupo de pacientes DLBCL novedoso, respectivamente. La presente invención se refiere además a un método para tratar DLBCL con obinutuzumab (o sus equivalentes funcionales) en un paciente en necesidad del mismo, en donde el paciente es un paciente con DLBCL definido por biomarcador particular o que pertenece a un subgrupo de pacientes DLBCL definido por biomarcador novedoso. La presente invención se refiere además al uso de obinutuzumab (o sus equivalentes funcionales) para la preparación de una composición farmacéutica para el tratamiento de DLBCL en el subgrupo de pacientes con DLBCL definido por biomarcador particular/paciente con DLBCL novedoso. La presente invención se refiere además a un método para identificar un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedoso y un método para diagnosticar una forma novedosa de DLBCL y un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedosos, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542489P | 2017-08-08 | 2017-08-08 | |
| PCT/EP2018/071462 WO2019030260A1 (en) | 2017-08-08 | 2018-08-08 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200061A true CR20200061A (es) | 2020-05-23 |
Family
ID=63209389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200061A CR20200061A (es) | 2017-08-08 | 2018-08-08 | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11597772B2 (es) |
| EP (1) | EP3665196B1 (es) |
| JP (2) | JP7418322B2 (es) |
| KR (1) | KR102799421B1 (es) |
| CN (2) | CN119798437A (es) |
| AU (1) | AU2018314765C1 (es) |
| CA (1) | CA3071618A1 (es) |
| CR (1) | CR20200061A (es) |
| ES (1) | ES2933256T3 (es) |
| IL (1) | IL272418B2 (es) |
| MA (1) | MA49830A (es) |
| MX (1) | MX2020001493A (es) |
| MY (1) | MY202382A (es) |
| PE (1) | PE20200738A1 (es) |
| PL (1) | PL3665196T3 (es) |
| SG (1) | SG11202000985XA (es) |
| TW (2) | TWI772488B (es) |
| UA (1) | UA126204C2 (es) |
| WO (1) | WO2019030260A1 (es) |
| ZA (1) | ZA202000680B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| IL272418B2 (en) | 2017-08-08 | 2024-09-01 | Hoffmann La Roche | Abinotuzumab treatment of a new subgroup of DLBCL patients |
| CN113260632A (zh) * | 2018-10-29 | 2021-08-13 | 蒂嘉特克斯公司 | 包含IgA抗体构建体的组合物和方法 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| AR125390A1 (es) * | 2021-04-21 | 2023-07-12 | Celgene Corp | Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona |
| IL305490A (en) * | 2021-04-21 | 2023-10-01 | Celgene Corp | Methods of treating b-cell lymphoma using combination therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0238090B1 (en) | 1986-03-20 | 1997-02-05 | Nec Corporation | Microcomputer capable of accessing internal memory at a desired variable access time |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| ES2923942T3 (es) * | 2013-11-06 | 2022-10-03 | Us Health | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| DE102013222576A1 (de) | 2013-11-06 | 2015-05-07 | BSH Bosch und Siemens Hausgeräte GmbH | Haushaltsgerät |
| JP6478989B2 (ja) | 2013-11-07 | 2019-03-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法 |
| RU2016141385A (ru) * | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| CN106794247B (zh) * | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| EP3302561A4 (en) * | 2015-06-08 | 2019-02-06 | Debiopharm International SA | COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES |
| KR20180012873A (ko) | 2015-06-24 | 2018-02-06 | 에프. 호프만-라 로슈 아게 | 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체 |
| EP3178848A1 (en) * | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| IL272418B2 (en) * | 2017-08-08 | 2024-09-01 | Hoffmann La Roche | Abinotuzumab treatment of a new subgroup of DLBCL patients |
-
2018
- 2018-08-08 IL IL272418A patent/IL272418B2/en unknown
- 2018-08-08 EP EP18755421.7A patent/EP3665196B1/en active Active
- 2018-08-08 AU AU2018314765A patent/AU2018314765C1/en active Active
- 2018-08-08 ES ES18755421T patent/ES2933256T3/es active Active
- 2018-08-08 PL PL18755421.7T patent/PL3665196T3/pl unknown
- 2018-08-08 CR CR20200061A patent/CR20200061A/es unknown
- 2018-08-08 UA UAA202001356A patent/UA126204C2/uk unknown
- 2018-08-08 SG SG11202000985XA patent/SG11202000985XA/en unknown
- 2018-08-08 JP JP2020505912A patent/JP7418322B2/ja active Active
- 2018-08-08 CN CN202411647297.0A patent/CN119798437A/zh active Pending
- 2018-08-08 TW TW107127631A patent/TWI772488B/zh active
- 2018-08-08 WO PCT/EP2018/071462 patent/WO2019030260A1/en not_active Ceased
- 2018-08-08 CN CN201880051243.4A patent/CN111032692A/zh active Pending
- 2018-08-08 PE PE2020000199A patent/PE20200738A1/es unknown
- 2018-08-08 KR KR1020207006102A patent/KR102799421B1/ko active Active
- 2018-08-08 MA MA049830A patent/MA49830A/fr unknown
- 2018-08-08 CA CA3071618A patent/CA3071618A1/en active Pending
- 2018-08-08 MX MX2020001493A patent/MX2020001493A/es unknown
- 2018-08-08 MY MYPI2020000328A patent/MY202382A/en unknown
- 2018-08-08 TW TW111133199A patent/TWI909088B/zh active
-
2020
- 2020-01-31 ZA ZA2020/00680A patent/ZA202000680B/en unknown
- 2020-02-06 US US16/784,021 patent/US11597772B2/en active Active
-
2023
- 2023-02-02 US US18/163,810 patent/US20230348611A1/en active Pending
- 2023-08-24 JP JP2023136335A patent/JP2023179425A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200061A (es) | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) | |
| MX2021006238A (es) | Metodos para tratamiento que usan terapia celular adoptiva. | |
| MX2020005165A (es) | Biogenesis de miarn en exosomas para diagnostico y terapia. | |
| MX2017001302A (es) | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. | |
| MX2017006268A (es) | Administracion intranasal. | |
| UY35013A (es) | Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos | |
| MX2018009738A (es) | Anticuerpos monoclonales de proteína ns1 anti-virus del dengue. | |
| MX2021006980A (es) | Anticuerpos anti-il-27 y usos de estos. | |
| MX2015009901A (es) | Administración de un compuesto de antiactivina a a un sujeto. | |
| BR112015022934A8 (pt) | esteróides neuroativos, composições e usos destes | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112018006045A2 (pt) | análise de marcador de massa para células raras e moléculas isentas de células | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MX2020009879A (es) | Anticuerpos anti-il-27 y sus usos. | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| CL2020001936A1 (es) | Métodos para el tratamiento de la atrofía muscular espinal. | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| BR112016023607A2 (pt) | uso médico de compostos de artemisinina e agonistas de gefirina | |
| MX2019003619A (es) | Formulaciones de bromocriptina. | |
| MX2022003719A (es) | Anticuerpos anti-il-27 y sus usos. | |
| MX381544B (es) | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. |